Chiesi Limited is a registered limited company operating in the United Kingdom, established in 1987. Currently, the company is active and maintains a strong focus on pharmaceutical innovation. Located at 333 Styal Road, Manchester, M22 5LG, Chiesi specializes in the research, development, and commercialization of novel therapeutic solutions within key areas of healthcare. The company’s core business revolves around addressing unmet medical needs, particularly within respiratory health, rare diseases, and specialty care. Chiesi’s strategic focus is on identifying and validating new drug candidates with significant therapeutic potential. Currently, Chiesi’s activities encompass a broad range of research and development efforts, including preclinical studies, clinical trials, and regulatory submissions. The company’s international presence is actively pursued through strategic partnerships and collaborations. As a skilled worker, Chiesi Limited is currently operating at a worker rating of A. The company’s size is estimated to be moderately sized, with a dedicated team of scientists, researchers, and business professionals. Chiesi’s key industry focus is pharmaceutical goods, with a specialization in the development of innovative treatments for complex medical conditions. The company’s SIC codes include -46460: Wholesale of pharmaceutical goods, reflecting its core business.

Chiesi Limited is a registered limited company operating in the United Kingdom, established in 1987. Currently, the company is active and maintains a strong focus on pharmaceutical innovation. Located at 333 Styal Road, Manchester, M22 5LG, Chiesi specializes in the research, development, and commercialization of novel therapeutic solutions within key areas of healthcare. The company’s core business revolves around addressing unmet medical needs, particularly within respiratory health, rare diseases, and specialty care. Chiesi’s strategic focus is on identifying and validating new drug candidates with significant therapeutic potential. Currently, Chiesi’s activities encompass a broad range of research and development efforts, including preclinical studies, clinical trials, and regulatory submissions. The company’s international presence is actively pursued through strategic partnerships and collaborations. As a skilled worker, Chiesi Limited is currently operating at a worker rating of A. The company’s size is estimated to be moderately sized, with a dedicated team of scientists, researchers, and business professionals. Chiesi’s key industry focus is pharmaceutical goods, with a specialization in the development of innovative treatments for complex medical conditions. The company’s SIC codes include -46460: Wholesale of pharmaceutical goods, reflecting its core business.